Vertex Provides Pipeline and Business Updates in Advance of …
2 days ago · BOSTON--(BUSINESS WIRE)--Jan. 12, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 a.m. ET / 7:30 a.m. …
Newsroom | Vertex Pharmaceuticals Newsroom
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Vertex Provides Pipeline and Business Updates in Advance of …
1 day ago · BOSTON, January 12, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s ...
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You …
Dec 26, 2024 · Vertex Pharmaceuticals (VRTX -0.62%) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial.
Vertex Pharmaceuticals: Balancing Growth Prospects and …
16 hours ago · Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of ...
Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug.
Oct 24, 2024 · Vertex's push to diversify its portfolio of medicines away from its traditional wheelhouse, drugs for cystic fibrosis (CF), looks like it's on the verge of bearing fruit once again.
Vertex's painkiller results match placebo in study, shares tumble
Dec 19, 2024 · Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed little difference versus a placebo in reducing pain, sending its...
Press Releases | Vertex Pharmaceuticals Newsroom
BOSTON -- (BUSINESS WIRE)--Oct. 10, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after …
Press Release - Vertex Pharmaceuticals Newsroom
Apr 10, 2024 · Alpine’s lead molecule, povetacicept (ALPN-303), is a highly potent and effective dual antagonist of BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand). Through Phase 2 development, povetacicept has shown potential best-in-class efficacy in IgA nephropathy (IgAN).
News & Events - Vertex Pharmaceuticals
Jun 23, 2023 · BOSTON--(BUSINESS WIRE)--Jun. 23, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented data on all patients dosed in Parts A and B of its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic ...
- Some results have been removed